"diffuse large b cell" trang 2 - tải miễn phí từ tailieunhanh
Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma

Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma
7    49    1
Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: A single center experience

Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: A single center experience
8    30    1
Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma

Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma
12    68    1
Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement

Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement
7    33    1
Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma
7    64    1
MYC and BCL2 overexpression is associated with a higher class of Memorial SloanKettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system

MYC and BCL2 overexpression is associated with a higher class of Memorial SloanKettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system
11    93    1
Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas

Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas
10    33    1
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: A population-based analysis

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: A population-based analysis
11    47    1
Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: A prospective, observational study

Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: A prospective, observational study
6    40    1
Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
11    50    1
Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma

Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma
6    72    1
Network meta-analysis of targeted therapies for diffuse large B cell lymphoma

Network meta-analysis of targeted therapies for diffuse large B cell lymphoma
10    28    1
Clinical and prognostic features of non hodgkin lymphoma and preliminary effective evaluation of R-chop regimen in patients with diffuse large B-cell lymphoma

Clinical and prognostic features of non hodgkin lymphoma and preliminary effective evaluation of R-chop regimen in patients with diffuse large B-cell lymphoma
8    65    1
Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma

Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma
14    56    1
Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: A retrospective analysis

Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: A retrospective analysis
9    61    1
Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma

Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma
10    17    1
An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma

An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma
17    1    1
Histone regulator KAT2A acts as a potential biomarker related to tumor microenvironment and prognosis of diffuse large B cell lymphoma

Histone regulator KAT2A acts as a potential biomarker related to tumor microenvironment and prognosis of diffuse large B cell lymphoma
15    6    1
Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome

Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome
11    4    1
Prognostic impact of pretreatment skeletal muscle index and CONUT score in diffuse large B-cell Lymphoma

Prognostic impact of pretreatment skeletal muscle index and CONUT score in diffuse large B-cell Lymphoma
10    6    1